|
|
|
Clinical efficacy of raltitrexed by transcatheter arterial chemoembolization
n the treatment of advanced primary liver cancer |
| CHEN Gang1*, WU Jian1, GAO Jianwei1, ZHANG Mei2, HAN Xinqiang1, SHENG Yuguo1 |
1 Department of Interventional Vascular Surgery, Binzhou Medical University Hospital, Binzhou 256603, Shandong, P.R.China;
2 Department of Interventional Catheterization, Binzhou Medical University Hospital, Binzhou 256603, Shandong, P.R.China |
|
|
|
|
Abstract Objective To investigate the clinical efficacy and safety of the transcatheter arterial chemoembolization with raltitrexed and lipiodol emulsion in the treatment of advanced primary liver cancer.Methods The clinical data of 80 patients with inoperable primary and advanced liver cancer admitted to our department were studied. According to the treatment plan, they were divided into the treatment group and the control group, with 40 patients in each group. The short-term (1 month after surgery) efficacy of the two groups of patients was observed, including the median disease progression time, 1-year and 2-year survival rate, serum tumor markers (AFP, CA19-9), changes of transaminase and bilirubin, and adverse reactions.Results Three months after operation, RR and DCR in the treatment group were higher than those in the control group (P<0.01); the 1-year and 2-year survival rates in the treatment group were 81.6% and 57.5%, respectively, which were significantly higher than those in the control group (67.0% and 35.9%, respectively, P<0.05); median survival time in the treatment group was 11.6 months, higher than 7.3 months in the control group (P<0.05); the number of AFP, CEA, transaminase and bilirubin decreased in the treatment group 1 month after operation was higher than that in the control group (P<0.05); the comparison of the incidence of adverse reactions between the two groups showed no statistical significance (P<0.05).Conclusion The clinical efficacy and safety of retetroxel and iodized oil in the treatment of advanced primary liver cancer by intra-arterial embolization were significant.
|
|
Received: 13 May 2020
|
|
|
|
|
|
[1] VALERY P C,LAVERSANNE M,CLARK P J,et al.Projections of primary liver cancer to 2030 in 30 countries worldwide[J].Hepatology,2018,67(2)):600-611.
[2] HE X K,LIN Z H,QIAN Y,et al.Marital status and survival in patients with primary liver cancer[J].Oncotarget,2017,8(39):64954-64963.
[3] AKINYEMIJU T,ABERA S,AHMED M,et al.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global,regional,and national level: results from the global burden of disease study 2015[J].Jama Oncology,2017,3(12):1683-1691.
[4] ZHOU B,WANG J,YAN Z,et al.Liver cancer: effects,safety,and cost-effectiveness of controlled-release oxycodone for pain control after TACE[J].Radiology,2012,262(3):1014-21..
[5] 中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].传染病信息,2017,16(7):705-720.
[6] 黄洁夫,李绍强,梁力建.肝动脉化疗栓塞在原发性肝癌治疗中的地位和作用[J].中华肝胆外科杂志,2000,6(1):3-6. |
|
|
|
